Senores Pharmaceuticals: A Quarter of Robust Growth and Strategic Expansion

Senores Pharmaceuticals Limited, a global research-driven pharmaceutical company specializing in specialty, niche, and complex products, has announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company delivered a strong performance, marked by significant revenue and profit growth, driven by strategic initiatives and robust market expansion across its key segments.

For Q3 FY26, Senores Pharmaceuticals reported a consolidated total income of INR 174.6 crores, reflecting a substantial 64% year-on-year growth. This impressive top-line performance translated into a consolidated Profit After Tax (PAT) of INR 33.6 crores, an outstanding 104.7% increase compared to the previous year. The company's EBITDA also surged by 85.9% to INR 54.0 crores, with an EBITDA margin of 30.9%, improving by 360 basis points year-on-year. For the nine-month period (9M FY26), total income reached INR 474.3 crores, a 65% increase, while PAT more than doubled to INR 84.9 crores, growing by 110.3%.

Segmental Performance and Strategic Drivers

The growth was broad-based, with significant contributions from both Regulated and Emerging Markets. The Regulated Markets segment, primarily serving the US, Canada, and UK, recorded revenue of INR 112.7 crores in Q3 FY26, a 60.5% year-on-year increase. For 9M FY26, this segment's revenue grew by 71.5% to INR 309.6 crores, with an EBITDA margin consistently at 40%. This performance was bolstered by product portfolio expansion and prudent selection of sales channels.

The Emerging Markets business achieved its highest-ever quarterly revenue and EBITDA in Q3 FY26. Revenue for this segment grew by 47.5% year-on-year to INR 38.4 crores, with the EBITDA margin significantly improving from 1% in Q3 FY25 to 13% in Q3 FY26. This segment has also become cash-flow positive, driven by a shift towards niche products and a refined go-to-market strategy. The company has 450 approved products and 858 products under registration in over 40 countries within this segment.

Senores' Branded Generics business in India also witnessed exceptional growth, with revenue increasing more than six-fold year-on-year to INR 10.5 crores in Q3 FY26. This segment's strong momentum is attributed to product acceptance and customer adoption, with the company now supplying to multiple large hospital chains across India.

Strategic Acquisitions and Future Outlook

A key highlight of the quarter was the completion of the Phase 1 acquisition of a 75% stake in Apnar Pharma Private Limited. This acquisition is a strategic move to expand Senores' manufacturing footprint and product portfolio, particularly for regulated markets like the US, UK, and Canada. Apnar's US FDA-approved facility, with its expansion-ready infrastructure, is expected to generate positive cash flow, with three of its five approved ANDAs slated for launch in Q4 FY26. The integration and scale-up of Apnar Pharma's business are progressing faster than anticipated, enhancing scalability, market access, and operating leverage.

Senores boasts a robust product pipeline, with 46 approved ANDAs covering 137 strengths, and an additional 22 ANDAs under development. The company expects to launch 28 approved ANDAs and 10 pipeline products within the next 6-8 quarters, providing strong growth visibility. Furthermore, the company is enhancing its backward integration capabilities by increasing API manufacturing capacity from 25 MTPA to 169 MTPA through a greenfield unit, aiming to reduce reliance on third-party vendors and improve margins.

Management Confidence and Strategic Pillars

Management expressed confidence in achieving its FY26 targets of 50% top-line growth and 100% PAT growth over FY25. They anticipate branded generics revenue to reach INR 40-50 crores in FY26 and over INR 80 crores in FY27, with emerging market revenue projected at INR 170-180 crores next year. The consolidated EBITDA margin for FY26 is expected to be around 30%, with emerging market EBITDA margins stabilizing at 18-22% in FY27. The company plans a capex of INR 50-100 crores over the next two to three years.

Senores Pharmaceuticals is well-positioned for sustained growth, focusing on four key pillars: expanding the ANDA portfolio in Regulated Markets, steadily scaling up the CDMO/CMO segment, improving profitability in Emerging Markets through portfolio expansion, and scaling up the Branded Generics business in India. The company's proactive approach to market trends, disciplined capital allocation, and transparent communication underscore its commitment to long-term value creation for stakeholders.